EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.72 USD | -0.80% |
|
+1.72% | +13.73% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 6.56B | Sales 2025 * | 7.2B | Capitalization | 52.26B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.62B | Net income 2025 * | 1.86B | EV / Sales 2024 * | 7.71 x |
| Net cash position 2024 * | 1.68B | Net cash position 2025 * | 2.84B | EV / Sales 2025 * | 6.86 x |
| P/E ratio 2024 * |
32.6
x | P/E ratio 2025 * |
28.2
x | Employees | 19,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.6% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 day | -0.80% | ||
| 1 week | +1.72% | ||
| Current month | +2.42% | ||
| 1 month | -5.23% | ||
| 3 months | +2.01% | ||
| 6 months | +35.06% | ||
| Current year | +13.73% |
1 week
84.81
88.09
1 month
83.5091.73
Current year
71.6796.12
1 year
60.5796.12
3 years
60.57131.73
5 years
51.51131.73
10 years
13.02131.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 14-12-31 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 13-12-31 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 16-07-04 |
| Chairman | 67 | 14-11-12 | |
Steven Loranger
BRD | Director/Board Member | 72 | 16-03-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 0 M€ | +2.11% | - | |
| 2.34% | 0 M€ | +7.69% | - | |
| 2.13% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 86.72 | -0.80% | 1,988,029 |
| 24-05-09 | 87.42 | +2.74% | 3,421,901 |
| 24-05-08 | 85.09 | -0.87% | 1,727,855 |
| 24-05-07 | 85.84 | +0.88% | 1,836,563 |
| 24-05-06 | 85.09 | -0.19% | 2,449,673 |
Delayed Quote Nyse, May 10, 2024 at 04:00 pm EDT
More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
86.72
USD
Average target price
95.27
USD
Spread / Average Target
+9.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.73% | 52.26B | |
| +11.73% | 226B | |
| +9.53% | 188B | |
| +14.63% | 137B | |
| +27.47% | 108B | |
| -0.04% | 63.19B | |
| +4.86% | 51B | |
| +7.72% | 43.89B | |
| +7.86% | 38.07B | |
| +24.30% | 31.41B |
- Stock Market
- Equities
- EW Stock